2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | FKBP1A,FKBP1 |
| Accession | P62942 |
| Amino Acid Sequence | Met1-Glu108(F37V) with His Tag at the C-Terminus |
| Expression System | E. coli |
| Molecular Weight | 10-15kDa (Reducing) |
| Endotoxin | <0.1EU/μg |
| Tag | His Tag |
| Physical Appearance | Liquid |
| Storage Buffer | 50mM Tris-HCl,200mM NaCl,20% glycerol,pH7.5 |
| Stability & Storage | Stable for 12 months upon stored at -80℃ from the date ofreceipt. And avoid repeated freeze-thaws cycles. |
| Reference |
1.Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, Wong KK, Gray NS, Bradner JE. The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol. 2018 May;14(5):431-441. 2.Nabet, B., Ferguson, F.M., Seong, B.K.A. et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat Commun 11, 4687 (2020). 3.Juvvadi PR, Bobay BG, Gobeil SMC, Cole DC, Venters RA, Heitman J, Spicer LD, Steinbach WJ. FKBP12 dimerization mutations effect FK506 binding and differentially alter calcineurin inhibition in the human pathogen Aspergillus fumigatus. Biochem Biophys Res Commun. 2020 May 21;526(1):48-54. |
Background
FKBP12(F36V) is an engineered mutant of the human FKBP12 protein in which the phenylalanine at position 36 is replaced by valine. This mutation introduces an additional hydrophobic pocket in the ligand-binding site, enabling it to bind synthetic ligands bearing a "bump" group (such as AP1903 and dTAG-13) with sub-nanomolar affinity, while showing extremely low affinity for wild-type FKBP12, thereby achieving orthogonal recognition. Functionally, it is widely used as a regulatory component in chemical-induced dimerization (CID) systems and as a tag in the dTAG-induced degradation system, allowing reversible and precise control over the function or abundance of target proteins. Clinically, the iCasp9 safety switch based on FKBP12(F36V) has entered clinical trials; infusion of the dimerizing drug AP1903 can rapidly eliminate alloreactive T cells in graft-versus-host disease, demonstrating controllable safety regulation potential.
Picture
Picture
SDS-PAGE

SPR

CM5 Chip captured FKBP12(F37V) His Tag Protein, Human (Cat. No. UA085072), can bind Tacrolimus with an affinity constant of 24.53nM as determined in SPR assay.
